Immunome (NASDAQ:IMNM) Rating Lowered to “Strong Sell” at Wall Street Zen

Immunome (NASDAQ:IMNM) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday.

IMNM has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Barclays assumed coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective on the stock. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Wedbush boosted their price objective on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Immunome Stock Performance

Shares of IMNM stock opened at $27.20 on Friday. Immunome has a twelve month low of $8.66 and a twelve month high of $28.62. The stock has a fifty day simple moving average of $22.20 and a two-hundred day simple moving average of $22.21. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -10.75 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Research analysts predict that Immunome will post -2.3 EPS for the current fiscal year.

Insider Activity

In other Immunome news, insider Kinney Horn sold 90,616 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the sale, the insider owned 50,366 shares in the company, valued at approximately $1,263,682.94. The trade was a 64.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the transaction, the director owned 92,211 shares in the company, valued at approximately $2,512,749.75. This trade represents a 10.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 682,310 shares of company stock valued at $15,675,566 over the last ninety days. 7.21% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP purchased a new stake in Immunome in the 2nd quarter worth $25,000. KBC Group NV acquired a new stake in shares of Immunome in the first quarter valued at about $60,000. Strs Ohio acquired a new stake in shares of Immunome in the fourth quarter valued at about $64,000. Assetmark Inc. increased its stake in shares of Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after purchasing an additional 1,442 shares in the last quarter. Finally, State of Wyoming purchased a new stake in shares of Immunome during the second quarter worth about $109,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.